Research programme: retinoids - Biomedica Life SciencesAlternative Names: RASP
Latest Information Update: 14 Jul 2016
At a glance
- Originator Biomedica Life Sciences
- Developer Biomedica Life Sciences; University of Patras
- Class Retinoids
- Mechanism of Action Ribonuclease P inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin cancer
Most Recent Events
- 14 Jul 2016 Preclinical trials in Skin cancer in Greece (unspecified route) before July 2016